Abstract
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that (in addition to overlapping data panels internally within the figure, suggesting that some of the data had been derived from the same original sources where the results of differently performed experiments were intended to have been portrayed) certain of the data featured in Fig.5A on p.2123 had already been published in another article written by different authors at different research institutes [TianF, Ding D and Li D: Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells. Int J Oncol46: 2355‑2363, 2015]. Owing to the fact that the contentious data in the above article had already been published prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 49: 2116‑2126, 2016; DOI: 10.3892/ijo.2016.3708].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
